Searched for
MARGIN EROSION
ET Prime Special Series: Multibagger or Bankrupt - Part 65: This auto ancillary is making new moves. Separate signal from noiseThis supplier is one of those businesses that grows quietly until it suddenly makes several big decisions at once. In a short span it has s...- PSBs raise term deposit rates to reclaim deposit market sharePublic sector banks are boosting term deposit rates to reclaim lost market share, a move that contrasts with private banks lowering theirs....
- Rs 19 lakh crore shocker! TCS, Infosys & 2 IT giants crash 50% from peak: Is the absolute worst yet to come?India's top IT firms, including TCS and Infosys, have seen their market value plummet by at least 50% from peak levels, erasing nearly Rs 1...
- India's underperformance sets stage for recovery, says JM Financial's Deepak GuptaIndian equities are showing signs of a potential rebound, with attractive valuations and improved currency stability, according to Deepak G...
- Supply recovery, not demand, will be oil market's key test: Vandana HariGlobal crude oil prices have fallen significantly from wartime highs, but market expert Vandana Hari cautions against declaring victory. Sh...
- Can Elon Musk do to US telecom what Mukesh Ambani did in India?Elon Musk's Starlink is poised to disrupt American telecom giants like AT&T and Verizon. Analysts believe Starlink could change how connect...
- Pharma exports to US seen muted this yearIndian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...
- PSU bank stocks vs private banks in FY27: The valuation trap you need to avoidPSU banks achieved historic profit and NPA lows in FY26, yet analysts favor leading private banks for FY27. This shift is driven by superio...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Buy, Sell or Hold: Citi maintains buy on Eicher Motors; Goldman Sachs retains buy on Max HealthcareBrokerages maintain a positive outlook on select large-cap pharmaceutical, automobile, and healthcare stocks, citing strong growth prospect...
- Margin pressure, slower growth outlook may cap upside for Sun Pharma stockSun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and...
- Macro, the Mightiest: Why India’s biggest macro variable still falls from the skyThe 2026 monsoon comes with a clear warning: Rainfall is forecast at 92% of the long-period average, with higher-than-usual probability of ...
- Mcap of 6 of top-10 most valued firms surges by Rs 74,111 cr; Reliance biggest winner
- Adani turning back the clock: How two group stocks created Rs 1.3 lakh crore wealth in a lopsided Nifty yearAdani Enterprises and Adani Ports have generated over Rs 1.3 lakh crore in investor wealth this year. These two Adani Group stocks have sig...
- The 20 stocks mutual funds are buying with Rs 1 lakh crore to defy historic FII sellingIndian mutual funds are investing Rs 1.07 lakh crore in 20 key stocks to counter historic FII selling. They are focusing on large-cap priva...
- Ola Electric Q4 loss narrows 42.5% to Rs 500 crore, CEO Aggarwal bets on volume recoveryThe Bhavish Aggarwal-led company’s revenue from operations during the quarter declined 56.6% year-on-year (YoY) to Rs 265 crore from Rs 611...
- Waiting for your dream phone to get cheaper? That moment may never comeSmartphone prices are no longer dropping predictably. The demand for AI chips is causing component costs to surge. This means phones are la...
- Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...
- Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh inDr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...
- Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announcedDr Reddy's Laboratories Q4 Results: Dr. Reddy's Laboratories reported a consolidated net profit at Rs 221 crore in the March-ended quarter ...
Load More
